(UroToday.com) Despite advances in biomarker development, early detection of aggressive prostate cancer (Gleason Group 3-5) continues to pose significant clinical challenges. Several authors involved in this study previously developed the Michigan Prostate Score for individualized risk prediction of aggressive prostate cancer.1 The Michigan Prostate Score uses transcription-mediated amplification to quantify expression of TMPRSS2:ERG and PCA3 from whole urine obtained after a digital rectal exam, combined with serum PSA. To improve upon the Michigan Prostate Score, Dr. Salami and colleagues at the AUA 2020 virtual annual meeting presented results of their study describing the pre-clinical development and validation of a targeted next-generation RNA sequencing assay Michigan Prostate Score.